EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
Chaparro, M.; Barreiro de Acosta, Manuel; Benítez, J. M.; Casanova, M. J.; Ceballos, D.; Esteve, M.; Fernández, H.; Ginard, D.; Gomollón, F.; Lorente, R.; Nos, P.; Riestra, S.; Rivero, M.; Robledo, P.; Rodríguez, C.; Sicilia, B.; Torrella, E.; Garre, A.; García-Esquinas, E.; Rodríguez-Artalejo, F.; Gisbert, J.P.
Identificadores
Identificadores
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Autor corporativo
EpidemIBD study group of GETECCUData de publicación
2019Título da revista
Therapeutic advances in gastroenterology
Tipo de contido
Artigo
Resumo
Background: Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes.
Methods: This multicenter, population-based incidence cohort study included patients aged >18 years with IBD (Crohn's disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded.
Results: The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up.
Conclusions: The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD.